CanSino Bio launches $161m Hong Kong IPO
The management of vaccine developer CanSino Biologics has hit the road to market its IPO of up to HK$1.26bn ($161m).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: